Fin Stolze Larsen1, Peter Nissen Bjerring. 1. Department of Hepatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. stolze@post3.tele.dk
Abstract
PURPOSE OF REVIEW: Acute liver failure (ALF) results in a multitude of serious complications that often lead to multi-organ failure. This brief review focuses on the pathophysiological processes in ALF and how to manage these. RECENT FINDINGS: The clinical presentation in ALF ranges from slightly altered conscious level with profound coagulopathy to coma with a catastrophic failure of multiple organs, including uncontrollable cerebral edema and brain death, which is rarely seen in decompensated cirrhosis. Interestingly, ALF patients who recover as the liver is regenerating, usually do not suffer from hepatic or extrahepatic sequelae. In contrast patients surviving acute-on-chronic liver failure will return to a state with incompensated cirrhosis, and eventually need transplantation for survival.In the management of ALF, the use of noradrenalin in combination with continuous high-dose renal replacement therapy, terlipressin, hypertonic sodium chloride, and mannitol can ameliorate systemic vasodilation and attenuate brain edema. Furthermore, liver assist devices seem to improve extrahepatic organ dysfunction and survival. SUMMARY: Insight into the of pathopysiological mechanisms of ALF that lead to cardiovascular instability, brain edema and development of multiorgan failure has advanced and resulted in improved survival. The role of liver assisting is still unknown but preliminary results indicate a positive effect on survival.
PURPOSE OF REVIEW: Acute liver failure (ALF) results in a multitude of serious complications that often lead to multi-organ failure. This brief review focuses on the pathophysiological processes in ALF and how to manage these. RECENT FINDINGS: The clinical presentation in ALF ranges from slightly altered conscious level with profound coagulopathy to coma with a catastrophic failure of multiple organs, including uncontrollable cerebral edema and brain death, which is rarely seen in decompensated cirrhosis. Interestingly, ALFpatients who recover as the liver is regenerating, usually do not suffer from hepatic or extrahepatic sequelae. In contrast patients surviving acute-on-chronic liver failure will return to a state with incompensated cirrhosis, and eventually need transplantation for survival.In the management of ALF, the use of noradrenalin in combination with continuous high-dose renal replacement therapy, terlipressin, hypertonicsodium chloride, and mannitol can ameliorate systemic vasodilation and attenuate brain edema. Furthermore, liver assist devices seem to improve extrahepatic organ dysfunction and survival. SUMMARY: Insight into the of pathopysiological mechanisms of ALF that lead to cardiovascular instability, brain edema and development of multiorgan failure has advanced and resulted in improved survival. The role of liver assisting is still unknown but preliminary results indicate a positive effect on survival.